Previous Article | Next Article ![]()
Applied and Environmental Microbiology, August 2002, p. 3780-3789, Vol. 68, No. 8
0099-2240/02/$04.00+0 DOI: 10.1128/AEM.68.8.3780-3789.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Unité de Génétique des Génomes Bactériens,1 Laboratoire de Génomique des Microorganismes Pathogènes, Institut Pasteur, 75724 Paris Cedex 15, France,2 HKU-Pasteur Research Centre, Pokfulam, Hong Kong3
Received 25 January 2002/ Accepted 29 May 2002
|
|
|---|
|
|
|---|
Carbapenems are a class of ß-lactam antibiotics synthesized by a biochemical route distinct from that found in the biosynthetic pathways of the sulfur-ring ß-lactams, namely, penicillins, cephamycins, and cephalosporins (5, 43). As naturally produced metabolites, they were originally isolated in the late 1970s from Streptomyces species. The first carbapenem antibiotic discovered was thienamycin, produced in small quantities by Streptomyces cattleya (J. S. Kahan, F. M. Kahan, R. Goegelman, S. A. Currie, M. Jackson, E. O. Stapley, T. W. Miller, A. K. Miller, D. Hendlin, S. Mochales, S. Hernandez, and H. B. Woodruff, Program Abstr. 16th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 227, 1976). To date, over 40 naturally occurring carbapenems have been identified, the majority of which originate from streptomycetes. Carbapenems are broad-spectrum agents in their activity and relatively resistant to most of the clinically encountered bacterial ß-lactamases (4, 18, 29).
The genes responsible for the synthesis of the model carbapenem molecule, 1-carbapen-2-em-3-carboxylic acid (SQ27860, Car), which contains only an unsubstituted bicyclic ring system (6, 26), have recently been identified in two gram-negative enteric bacteria, Erwinia carotovora and Serratia sp. strain ATCC 39006. These consist of a cluster of nine genes (designed car) that encode a positive regulator of carbapenem gene expression (carR), five enzymes required for the construction of the carbapenem molecule (carABCDE), two proteins responsible for a novel ß-lactam resistance mechanism conferring carbapenem immunity in the producing host (carFG), and a protein of unknown function (carH). Genetic investigations have shown that the expression of car genes is regulated in both strains by quorum sensing. The first gene of the carbapenem cluster, carR, encodes a transcriptional activator that allows expression of the remaining downstream genes of the car cluster. In E. carotovora, CarR responds to a quorum-sensing, N-(3-oxohexanoyl)-L-homoserine lactone (OHHL), signaling molecule synthesized by the product of the unlinked carI gene. This OHHL-dependent transcriptional activation allows cells to coordinate the expression of carbapenem with cell density (22). In Serratia, the autoinducer synthase SmaI, which directs the synthesis of N-butanoyl-L-homoserine lactones (BHLs) and N-hexanoyl-L-homoserine lactone (HHL), is essential for the full transcription of the carbapenem biosynthetic genes. A second regulatory gene affecting expression of carbapenem in Serratia (the rap gene) and E. carotovora (its homolog hor) has also been identified elsewhere (39, 40).
In this report the characterization for P. luminescens of a cluster of genes (named cpmA to cpmH) responsible for the biosynthesis of a carbapenem-like antibiotic is described. Although this cluster shows significant sequence similarities with the car operon, previously identified in E. carotovora and Serratia sp. strain ATCC 39006, it displays unique features and appears to be regulated differently than in the latter two species.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and plasmids
|
Assay for production of luxS-based signaling molecules.
An AI-2 bioassay using V. harveyi BB170 was performed as described previously (36) with some modifications. Briefly, V. harveyi BB170 was grown overnight with aeration at 30°C in AB medium and diluted 1:2,500 in fresh AB medium, and 27 ml of the diluted culture was added to 3 ml of cell-free P. luminescens supernatants in a 250-ml Erlenmeyer flask. Cultures were shaken at 200 rpm in a rotary shaker at 30°C, and light emission by V. harveyi BB170 was measured every 30 min with a photomultiplicator tube (PMT H5783 model; Hamamatsu) (41). Cell-free culture fluids were prepared from P. luminescens parental and luxS mutant strains by centrifugation (2 min at 4,500 x g) and filtration of supernatants through Millex-GP 0.22-µm-pore-size filters (Millipore). The supernatants were stored on ice before being assayed for luxS-based quorum-sensing activity. Three milliliters of Schneider sterile medium and V. harveyi BB152 cell-free culture fluid were used as negative and positive controls, respectively.
DNA manipulations and plasmid construction.
Chromosomal DNA preparation, ligation, E. coli electroporation, and Southern blotting were carried out by standard procedures (33). Plasmid DNA was isolated with the GenElute Plasmid Miniprep kit (Sigma). Restriction enzymes were obtained from Roche, and enzymatic reaction mixtures were purified with the MinElute Reaction Cleanup kit (Qiagen). To construct the pDIA600 plasmid, a DNA fragment containing an internal region of cpmA was generated by PCR with primers CpmA1 (5'-AAACTGCAGCCTGCTCCATGAGTTGAAAA-3') and CpmA2 (5'-GATCTAGTGTGCTTAGTGATGTGGA-3') and genomic DNA from P. luminescens TT01. The resulting 900-bp amplified fragment was purified with the QIAquick PCR purification kit (Qiagen) and restricted by XbaI (located inside the amplified sequence) and PstI (present in primer CpmA2), before being cloned into the pJQ200KS vector (27) in an inverse orientation with respect to the lacZ promoter. Plasmid pDIA602 was constructed via two steps of PCR amplification. Briefly, the chloramphenicol acetyltransferase gene of pACYC184 (Biolabs) was amplified by PCR with oligonucleotides Cat5 (5'-TTGATCGGCACGTAAGAGGT-3') and Cat3 (5'-AATTTCTGCCATTCATCCGC-3'), resulting in an 850-bp DNA fragment. Two 950-bp DNA fragments containing either the 5' upstream region of luxS or the end of the coding region of luxS and the downstream region were also PCR generated with either oligonucleotides luxS1 (5'-AAACTGCAGCTTTGGATGGGTGATCCCAT-3') and luxS2 (5'-ACCTCTTACGTGCCGATCAAGGATCCTCATCGTATCCTCACGTTCC-3') or oligonucleotides luxS3 (5'-GCGGATGAATGGCAGAAATTGGATCCGGCTATGGCTGATGTCTTGA-3') and luxS4 (5'-AGCTCTAGACGGCGACATTATGGTTCCCC-3'). The 21st bases of primers luxS2 and luxS3 are complementary to primers Cat5 and Cat3, respectively. After purification and quantification, 100 ng of each of the three previously amplified fragments was mixed and used as a template to generate a new 2,730-bp DNA fragment by a second PCR amplification with oligonucleotides lux1 and lux4. The latter amplicon, which corresponds to a luxS::Cm fragment, was purified, PstI and XbaI restricted, and ligated to the pJQ200KS vector (27) to yield pDIA602. To construct plasmid pDIA603, a 1.35-kb DNA fragment containing slyA was generated by PCR with primers SlyA10 (5'-AAACTGCAGCGTGAAGTATTGCGACTGTGC-3') and SlyA8 (5'-CCAAAATGTTCAGGGAGCTCTTAACAC-3') and genomic DNA from P. luminescens TT01. The amplified fragment was restricted by NaeI and SacI (both sites located inside the amplified sequence) and inserted at the SmaI and SacI sites of plasmid pBluescript SK+. A kanamycin resistance cassette obtained by BamHI restriction of pUC4K (Amersham Pharmacia Biotech) was then inserted into the latter vector at a BglII site located at the beginning of the slyA coding region. The slyA::Kan fragment was then cloned as an ApaI-SacI fragment at the same sites of the multiple cloning site of pJQ200KS to generate plasmid pDIA603.
Mutant construction.
P. luminescens mutant PL2101 was obtained by using vector pDIA600 delivered into strain TT01 by conjugal transfer from E. coli strain S17-1. Gentamicin-resistant colonies containing an integrated copy of this vector inside the cpmA locus were selected. Disruption of cpmA was confirmed by Southern blot hybridization with a PCR-amplified digoxigenin-labeled cpmA gene probe performed with oligonucleotides CpmA1 and CpmA2 with the PCR digoxigenin probe synthesis kit (Roche) (data not shown). P. luminescens luxS and slyA mutants, PL2102 and PL2103, respectively, were created via allelic exchange with plasmids pDIA602 and pDIA603, respectively. Both plasmids were transformed into E. coli S17-1 and introduced into P. luminescens by mating. Cmr Gms Sacr or Kanr Gms Sacr exconjugants were selected on proteose peptone agar (1% proteose peptone, 0.5% NaCl, 0.5% yeast extract, 15% agar) containing 2% sucrose. Insertions were confirmed by Southern blot analysis (data not shown).
Handling of RNA.
E. coli and P. luminescens total RNA was prepared from 10-ml cultures. Samples of bacterial cultures were collected by centrifugation for 2 min at 4°C at 6,000 x g and stored at -80°C to prevent RNA degradation. Bacterial pellets were resuspended in 500 µl of 25 mM Tris-HCl (pH 7.6)-60 mM EDTA solution and transferred into tubes containing 500 µl of acid phenol (pH 4.5) and 0.4 g of 0.1-mm-diameter glass beads (Sigma). Cells were mechanically broken with a Fastprep apparatus (Bio 101) as homogenizer (two 30-s cycles of homogenization at maximum speed with 1-min intervals on ice). RNA was then extracted and purified with the TRIzol reagent kit (Gibco-BRL) according to the manufacturer's recommendations. After isopropanol precipitation, RNA was redissolved in 100 µl of TE (10 mM Tris, 1 mM EDTA, pH 7.6) and incubated with RNase-free DNase I (DNA-free kit; Ambion) according to the manufacturer's protocol. RNA samples were then quantified by measuring A260 and A280. Both RNA purity and integrity were controlled by separating a sample on an agarose gel to ensure that mRNA, tRNA, and rRNA precursors could be seen.
Primer extension.
Reactions were performed according to standard procedures (33) with some modifications. Ten picomoles of end-labeled oligonucleotide was precipitated with ammonium acetate and ethanol at -20°C, washed with 70% ethanol, dried, and resuspended in 40 µl of diethylpyrocarbonate-treated TE buffer (10 mM Tris, 1 mM EDTA, pH 7.6) to a concentration of 2.5 ng/ml. Ten nanograms of primer was annealed with 50 µg of total RNA in avian myeloblastosis virus reverse transcriptase reaction buffer (Roche) and 1 mM deoxynucleoside triphosphates at 65°C for 10 min. The reaction was kept going while the temperature slowly decreased to 42°C. RNasin (20 U; Promega) was added, and the reaction was performed with 40 U of avian myeloblastosis virus reverse transcriptase (Roche) at 42°C for 90 min. One microliter of 0.5 M EDTA (pH 8) and 1 µl of DNase-free pancreatic RNase (Roche) were added, and the reaction mixture was further incubated at 37°C for 30 min. The reaction mixture was precipitated with ammonium acetate and ethanol, washed with 70% ethanol, and resuspended in formamide loading buffer. As a reference, sequencing reactions were performed with the Thermosequenase radiolabeled terminator cycle sequencing kit (Amersham) with the same primer used in primer extension experiments. The oligonucleotide used to map the 5' termini of cpm mRNA is CpmA7 (5'-CGGAAGAGTATGGTTCCAGTA-3').
Oligonucleotide labeling.
The oligonucleotides used in primer extension experiments were end labeled with phage T4 polynucleotide kinase (BioLabs) and [
-32P]ATP (3,000 Ci/mmol) according to standard procedures (33).
Nucleotide sequence accession numbers.
The 6,799- and 2,311-nucleotide sequences containing cpm clusters of P. luminescens have been assigned EMBL-EBI nucleotide sequence database (European entry point of the International Nucleotide Sequence Database) accession no. AJ457087 (cpmABCDEFGH) and AJ457088 (cpmIJK). Nucleotide sequences of P. luminescens luxS and slyA genes have been assigned database accession no. AJ457090 and AJ457089, respectively.
|
|
|---|
![]() View larger version (35K): [in a new window] |
FIG. 1. Comparison of the putative P. luminescens cpm operon with the car operon of E. carotovora and Serratia sp. strain ATCC 39006. (A) Map of the genes involved in carbapenem biosynthesis. (B) Amino acid sequence identity between Car and Cpm proteins of E. carotovora, Serratia sp., and P. luminescens.
|
Functional role of P. luminescens cpm operon.
On the basis of homology, we hypothesized that the cpm genes identified in P. luminescens might be involved in the biosynthesis of a carbapenem molecule as well as in carbapenem resistance. To obtain evidence about the presence of a carbapenem-like antimicrobial activity in P. luminescens, we tested diverse indicator strains for their sensitivity to P. luminescens (Table 1). These strains are clinical isolates that have developed resistance to ß-lactam antibiotics, including penicillins, cephalosporins, and carbapenems. An overlay of each indicator strain was poured onto an LB plate containing spotted P. luminescens colonies previously killed by exposure to chloroform. As shown in Fig. 2A, inhibition halos caused by antibiotic-induced cell killing were reproducibly observed with strains of E. coli, Klebsiella pneumoniae, and Enterobacter cloacae. No antibiosis was observed with the various imipenem-resistant clinical isolates of Pseudomonas aeruginosa, which have developed resistance to carbapenem by reducing the permeability of the outer membrane (32). Very small antibiosis zones were observed with a lawn of Xanthomonas maltophilia, a potent imipenemase strain. These results are consistent with the hypothesis that P. luminescens is a carbapenem producer and that Enterobacter cloacae is the species most sensitive to this ß-lactam compound. Antibiosis assays performed with an isogenic set of Enterobacter cloacae strains producing low or high levels of cephalosporinase confirmed our observations (Fig. 2B). Indeed, the parental strain exhibited a growth inhibition in the presence of P. luminescens while no inhibition halo was observed with the cephalosporinase derepressed derivative. These latter strains were therefore chosen to test carbapenem-like activity in the rest of this work.
![]() View larger version (74K): [in a new window] |
FIG. 2. Carbapenem-like activity of P. luminescens visualized by antibiosis. Three-day LB plates spotted with 5 µl of both TT01 (wild type) and mutants were inoculated with 100 µl of various ß-lactam indicator strain cultures (OD600 = 0.2) mixed in soft agar. Growth inhibition around a spot indicates production of antibiotics to which the indicator strain is sensitive. All experiments were repeated at least three times. (A) Analysis of carbapenem production and the effect of a cpmA mutation (PL2101) by antibiosis of lawns of various ß-lactam indicator strains. (B) Analysis of the effect of various mutations on the ability to produce carbapenem by antibiosis of lawns of Enterobacter cloacae strains C1 (cephalosporinase producer) and C1R (cephalosporinase derepressed). 1, cpmA mutation (PL2101); 2, luxS mutation (PL2102); 3, slyA mutation (PL2103).
|
Characterization and expression of the cpm cluster from P. luminescens.
Initial attempts to detect cpm mRNAs by reverse transcription-PCR suggested a very low level of cpmA expression (data not shown). Consequently, in order to map the transcription start point of the cpmA-to-cpmH putative operon, primer extension analysis was performed with a high quantity (50 µg) of RNA. P. luminescens total RNA was extracted during exponential growth phase and hybridized with primer CpmA7 specific for cpmA. The starting point is an adenosine residue located 69 bp upstream from the translation start codon of cpmA (Fig. 3B) and is preceded by -35 and -10 consensus sequences (TTGATA-16 bp-TACTAT ). Interestingly, the upstream region (from +1 up to -100) and the 5' untranslated region were particularly AT rich, 88 and 85%, respectively (Fig. 3A).
![]() View larger version (36K): [in a new window] |
FIG. 3. (A) Nucleotide sequence of the 5' region of cpmA from P. luminescens. Promoter sequences (-35 and -10 boxes) are boxed. The Shine-Dalgarno sequence (SD) is underlined. Only the first codons of the coding sequence of cpmA are shown in boldface. (B) Primer extension analysis of cpmA transcripts in P. luminescens. Total RNA was extracted from an exponential culture of P. luminescens TT01 grown at 30°C in Schneider medium (OD600 = 1.4). The arrow indicates the position of the extension product obtained.
|
![]() View larger version (41K): [in a new window] |
FIG. 4. (A) Primer extension analysis of cpm mRNA at various times during P. luminescens growth at 30°C in Schneider medium. Lanes: 1, early log growth (OD600 = 0.3); 2, log growth (OD600 = 1.0); 3, early stationary phase (OD600 = 4.0). Equal amounts of each RNA sample (50 µg) were used. Experiments were done in triplicate. The relative cpm mRNA abundances at different times during P. luminescens growth, with the lowest mRNA level taken as 1, are represented graphically. (B) P. luminescens growth curve indicating the different times when mRNAs were extracted. 1, early log growth (OD600 = 0.3); 2, log growth (OD600 = 1.0); 3, early stationary phase (OD600 = 4.0). Since P. luminescens synthesizes a variety of secondary metabolites which interfere with OD measurement at late exponential phase, correlations between CFU and OD measurements were used to define the various growth stages.
|
Although the AHL-based quorum sensing appears to be the predominant quorum signal used by host-associated gram-negative bacteria, another signaling pathway related to an alternate autoinducer (termed AI-2) has recently been discovered (34, 37). A gene involved in the new autoinducer synthesis, luxS, has been found in a large number of bacteria (19, 37). One homolog of luxS was identified in the P. luminescens genome, suggesting that P. luminescens directs the synthesis of this autoinducer. To examine whether P. luminescens produces such a molecule, we tested the ability of medium conditioned by P. luminescens cells to induce luminescence in the V. harveyi reporter strain BB170 (36). The results shown in Fig. 5A demonstrate that the addition of P. luminescens cell-free supernatant stimulates light emission in V. harveyi reporter strain BB170, while bioluminescence of BB170 was not increased by supernatant prepared from the luxS mutant PL2102 (see below). The level of luminescence induced by P. luminescens supernatant was about 15-fold lower than that measured upon addition of a positive control, V. harveyi BB152 cell-free supernatant. It has to be mentioned that, in contrast to V. harveyi BB152, P. luminescens supernatant was prepared from cells grown to a low cell density to preclude the production of antibiotics. Indeed, media conditioned by P. luminescens grown to higher cell density strongly inhibit V. harveyi BB170 growth (Fig. 5B). These results indicate that P. luminescens produces the new autoinducer AI-2 during exponential growth phase and that luxS is involved in this production.
![]() View larger version (25K): [in a new window] |
FIG. 5. P. luminescens production of a luxS-dependent AI-2 activity. (A) AI-2 bioassay of P. luminescens culture supernatants with V. harveyi BB170 as reporter. Ten percent cell-free supernatants were mixed with the reporter strain and incubated at 30°C on a rotary shaker. Light production was determined 4 h 30 min after the BB170 cells were mixed with the various cell-free supernatants (OD600 = 0.1). Cell-free culture fluids were prepared from P. luminescens parental (TT01) and luxS mutant (PL2102) strains grown to an OD600 of 1.0. Schneider sterile medium and V. harveyi BB152 cell-free culture fluid were used as negative and positive controls, respectively. (B) Inhibition of growth by P. luminescens cell-free supernatants. Cell-free supernatants were prepared from a wild-type P. luminescens strain grown in Schneider medium for 5 h (exponential phase; OD600 = 1.0) (open circles), 10 h (early stationary phase; OD600 = 4.0) (open triangles), and 15 h (stationary phase) (open diamonds). Ten percent (vol/vol) cell-free supernatants (open symbols) or sterile Schneider medium (filled squares) was added to the V. harveyi BB170 reporter strain, and cultures were incubated at 30°C on a rotary shaker.
|
![]() View larger version (29K): [in a new window] |
FIG. 6. Analysis of the effect of luxS and slyA mutations on growth rate and cpm mRNA synthesis. (A) Growth curve comparison among TT01 (filled squares), PL2102 (luxS mutant) (open triangles), and PL2103 (slyA mutant) (open circles) strains of P. luminescens. (B) Primer extension analysis of the effect of luxS mutation on cpm mRNA synthesis. RNA samples were taken at different times from cultures of TT01 and PL2102. Lanes: 1, log growth (OD600 = 1.0); 2, early stationary phase (OD600 = 4.0). (C) Primer extension analysis of the effect of slyA mutation on cpm mRNA synthesis. RNA samples were taken from exponential-growth-phase cultures of TT01 and PL2103 (OD600 = 0.9). Three independent primer extension analyses were performed. Equal amounts of each RNA sample (50 µg) were used. The relative cpm mRNA abundances measured in TT01 and mutants, with the lowest mRNA level taken as 1, are represented graphically. Error bars represent standard errors of the mean. Statistical analysis was performed with a Student t test, resulting in a significant difference (P < 0.05).
|
|
|
|---|
Antibiotic plate assays with various ß-lactam-resistant indicator strains confirmed the production of a carbapenem-like molecule by P. luminescens. This compound was shown to be effective against E. coli, K. pneumoniae, and Enterobacter cloacae. It was ineffective against imipenem-resistant clinical isolates of Pseudomonas species and had little, if any, inhibitory effect on X. maltophilia. Our results also showed that carbapenem is clearly not the sole antibiotic produced by P. luminescens. Indeed, growth inhibition zones were still observed in the presence of a cpm mutation. Furthermore, the carbapenem-like molecule produced by P. luminescens is not effective against gram-positive bacteria, as no difference in growth inhibition halo size could be detected in antibiosis assays performed with bacteria of this class and either a wild-type or a cpm mutant strain of P. luminescens. The two strains similarly inhibit gram-positive bacterial growth (data not shown). The discovery of a new ß-lactam antibiotic synthesized by the TT01 strain enlarges the spectrum of antibiotics known to be produced by P. luminescens. It is thought that the role of antibiotic production by P. luminescens is in keeping the insect carcass from putrefying after the bacterium-nematode infection, thereby maintaining a pure culture of P. luminescens inside the infected insect. This is a necessity for the successful completion of the nematode life cycle and for symbiont transmission to the nematode's progeny. Indeed, in the insect hemolymph, the infective nematode develops into hermaphrodites with eggs, but its offspring is unable to develop beyond the first juvenile stage (J1) without the presence of the symbiotic bacteria (17). When the symbiont dominates the microbial flora, nematodes subsequently develop into the nonfeeding infective juvenile stage (DJ), retain the symbiotic bacteria in the intestine, and emerge from the insect carcass in search of a new host (13).
Comparative sequence analysis of the cpm cluster of P. luminescens with those found in E. carotovora and Serratia spp. revealed unique features. The P. luminescens genome contains two copies of the last three genes, i.e., cpmFGH and cpmIJK, at distinct loci. The cpmIJK cluster is located near a gene homologous to penicillin binding protein B (38) and several genes showing homology to bacteriocin and immunity proteins (31). This location suggests that the yet-uncharacterized carbapenem self-resistance mechanism encoded by cpmF and cpmG may have a more general role. Although there is no evidence for the involvement of cpmH in either carbapenem biosynthesis or carbapenem resistance (23), its position immediately downstream of cpmF and cpmG, even at the second cpm unrelated locus, strongly suggests that it is involved in some aspect of carbapenem resistance.
Remarkably, carR, the gene located upstream of the carA to carH genes in Erwinia and Serratia, was not found in P. luminescens. The absence of this AHL-dependent activator suggests that the mechanism by which P. luminescens regulates the biosynthesis of its carbapenem-like compound is different from that described for Erwinia and Serratia. Carbapenem synthesis is not induced by AHL-based quorum sensing in P. luminescens. The finding that the P. luminescens genome does not contain any luxI homolog, the gene responsible for AHL synthesis, is surprising. Indeed, AHL appears to be the predominant quorum signal used by host-associated gram-negative bacteria (11), and it has been detected in Xenorhabdus nematophilus (10), another entomopathogenic bacterium symbiotically associated with nematodes (13). Moreover, as P. luminescens is a luminescent bacterium, it is expected that lux gene expression is controlled by the production of this autoinducer as in marine bacteria (9, 14). However, in accordance with the result of our BLAST comparisons, previous experiments looking for the accumulation of inducing activity have shown no indication of control of luminescence via autoinduction by AHLs in P. luminescens (14).
As with the Erwinia and Serratia car genes, the cpmA to cpmH expression in P. luminescens is positively regulated by a Rap/Hor homolog, SlyA (40). However, rather than a defective phenotype observed in those species, slyA disruption resulted only in a lower carbapenem production in P. luminescens. SlyA is a member of a growing family of transcriptional regulators which control diverse physiological processes in human, animal, and plant pathogens (28, 39). The mechanism by which they exert their influence is currently unknown (8, 42), as members of this family do not have any of the motifs common among other regulatory proteins such as helix-turn-helix motifs or zinc finger proteins (25). Further studies are therefore necessary to understand the nature of SlyA influence on carbapenem biosynthesis genes in P. luminescens.
Finally, the luxS-based quorum-sensing system, used by a variety of bacteria for communication (37), was shown to control the production of a carbapenem-like compound in P. luminescens. The luxS-mediated pathway negatively controls carbapenem biosynthesis gene expression. The cpmA mRNA amount detected in PL2102 was higher than that found in the wild type, especially during late-exponential growth phase. This quorum-sensing regulatory mechanism likely functions to limit carbapenem biosynthesis gene expression to the exponential growth phase. This timing must be important to ensure the monoxenic conditions for nematode reproduction at the moment of the insect death (about 24 to 48 h after infection). At this stage, P. luminescens bacteria have been growing rapidly and progressively enter into stationary phase (7). Carbapenem production before this period likely allows P. luminescens to inhibit most of the insect gut microflora and to avoid therefore their invasion of the insect body at the moment of insect death. Carbapenem secreted by P. luminescens is indeed active mainly against gram-negative bacteria and especially the family Enterobacteriaceae. It could also itself be used as some type of quorum sensing, when the bacterial concentration is still low. Furthermore, it may be important for bacteria not to be intoxicated by their own antibiotic production, since they are confined to a close medium. Other antibiotics produced may help to control the microflora or, if they are produced later, may be important to prevent contamination of the cadaver by other soil or water microorganisms. In contrast with P. luminescens, where carbapenem production occurs in exponential growth phase, cell-density-dependent regulation in Erwinia and Serratia allows carbapenem to be maximally expressed only at relatively high cell concentrations (1, 40). In Erwinia, harnessing the regulation of virulence factors and carbapenem to population size ensures that plant defenses are quickly overwhelmed while minimizing bacterial competition for ensuing resources by antibiotic production. P. luminescens, unlike Erwinia, does not have to quickly overwhelm host defense, as it uses a protective vector, its nematode, to be inoculated directly into the insect open blood circulation system. Moreover, its vector, which is not recognized as nonself by the host immune system, possesses several weapons (i.e., helminthic toxins and an immune-depressive factor) against the insect defense system to protect its bacterial symbiont (3, 15).
The complete elucidation of the genome sequence of strain TT01 of P. luminescens would allow us to identify other loci involved in the biosynthesis of the P. luminescens antimicrobial agents active against gram-positive bacteria, yeasts, and some fungi, as well as genes encoding potential antivertebrate virulence factors or a specific mechanism for self-protection. This will undoubtedly contribute to a better understanding of the biology of this insect pathogen.
Financial support came from the Institut Pasteur, the Centre National de la Recherche Scientifique (URA 2171), and the French ASG program supported by Aventis CropScience, the Institut Pasteur, INRA, and the Ministry of Industry.
Present address: Laboratory of Microbiology, SCK/CEN, Boeretang 200, 2400 Mol, Belgium. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»